Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Nov 29, 2022 9:26am
120 Views
Post# 35136238

RE:RE:RE:RE:RE:RE:Andrew CEO

RE:RE:RE:RE:RE:RE:Andrew CEOYes,

We really do not  know  how this will turn out.   A  new leader  who communicates in a better fashion than we had in the past is very welcome.

It is probably a good bet that all this  euphoria  will subside over the minimum 9  months until  either the injector  or the arbitration come to fruition.  (hopefully in a manner positive to Replicel)

Even though the  die-hard longterm shareholders on this board seem overly extatic  ,  I  do not see the market jumping up and down about  the current developments.  Often market movements precede actual outcomes.

Hasn't  even  gone back to  what I  had hoped was our low point of  $0.25   where we were a little while ago.

Interesting that  most of the activity  is in Asia  where the  markets are not really as good  as say North America.  Why  is  there not  more emphasis  on the North American  market  from a development perspective.

Anyway,  my  personal feeling is  we have another long wait  and see period  and just  hope  things turn a bit brighter in the New Year.

GLTA
<< Previous
Bullboard Posts
Next >>